Multiple Sclerosis Flowsheet Deemed Acceptable by Clinicians and Staff
Research shows the Multiple Sclerosis Flowsheet database has demonstrated acceptability among staff and clinicians.
CMSC 2019
Complete Coverage
Efficacy of ADS-5102 Extended Release for Impaired Walking in Multiple Sclerosis
The investigators of this Phase 3 study sought to evaluate the efficacy and safety of ADS-5102 (amantadine) extended-release capsules to treat multiple sclerosis patients with walking impairment.
Focused Healthcare Practitioner Discussion Improves MS Relapse Outcomes
Interactive discussions with healthcare practitioners (HCPs) and patient education regarding multiple sclerosis (MS) relapse increases the likelihood of patients reporting relapses and achieving more proactive disease management
Long-Term Reductions in MS Disability Progression After Ocrelizumab Treatment
Study evaluates the benefits of ocrelizumab on 48-week confirmed disability progression in MS observed in pooled OPERA I and OPERA II, as well as a 3 year ocrelizumab treatment in an open-label extension.
Integrative Medicine Model Shows Efficacy in Improving MS Treatment
Study demonstrated efficacy in improving communication with the clinician, lowering the number of visits, and improving the coordination of single-day multi-service and therapeutic interventions in multiple sclerosis
Structured Algorithm to Optimize Relapse Management in Multiple Sclerosis
The clinician workgroup achieved a consensus and report a 3-step iterative management algorithm for MS relapses.
Arbaclofen Extended-Release Effective, Tolerable in Treating MS Spasticity
Investigators sought to determine the safety and efficacy of twice-daily dosing of arbaclofen ER in patients with spasticity due to multiple sclerosis.
Dimethyl Fumarate Linked With Vulnerability to Herpes Simplex Encephalitis
Individuals with multiple sclerosis undergoing dimethyl fumarate therapy may be vulnerable to herpes simplex encephalitis.
Alemtuzumab Improves Quality of Life in MS Despite Thyroid Adverse Events
Despite the occurrence of thyroid adverse events or their severity, AEs had a minimal impact on quality of life for patients with relapsing-remitting multiple sclerosis who had been treated with alemtuzumab.
Siponimod Treatment for Secondary Progressive MS: Neurologist Expectations
Investigators hypothesize siponimod will function as an alternative therapeutic choice to monoclonal antibodies in MS.
Disease-Modifying Therapy Use Patterns in Pediatric Multiple Sclerosis
Investigators examine the use treatment patterns and utilization of disease-modifying therapy in newly diagnosed pediatric patients with multiple sclerosis.
Alemtuzumab Improves Clinical, MRI Outcomes in MS Across all Age Groups
Investigators sought to determine the 8-year safety and efficacy of alemtuzumab in patients with relapsing-remitting multiple sclerosis from the CARE-MS I and II studies.
Long DMD Lapses Associated With Higher Relapses, Resource Use, and Costs
Patients with multiple sclerosis with a lapse of >60 days of therapy may result in more lapses, resource use, and higher cost.
Comorbidity and Concomitant Medications Vary by Age and Sex in MS
Age- and sex-stratified comorbidity and concomitant medication use has been found among individuals with MS who have newly initiated disease-modifying drugs.
Alemtuzumab is Effective to Treat RRMS in Patients of African Descent
The investigators of this study sought to evaluate the long-term efficacy and safety of alemtuzumab to treat patients of African descent who have relapsing-remitting MS.
Want to read more?
Please login or register first to view this content.
Next post in CMSC 2019 Coverage
